The subscription period in IRLAB’s rights issue commences today

June 11, 2026

Today, 11 June 2026, the subscription period commences in IRLAB Therapeutics AB’s (“IRLAB” or the “Company”) issue of ordinary shares of series A with preferential rights for existing shareholders up to approximately SEK 68 million (the “Rights Issue”), which was resolved by the Board of Directors on 5 May 2026 and was approved by the Extraordinary General Meeting on 5 June 2026. The subscription period in the Rights Issue will run until 25 June 2026. However, please note that certain banks and nominees may apply an earlier deadline for subscription. Shareholders are therefore advised to check with their bank or nominee regarding any earlier deadline that may apply.

Today, 11 June 2026, the subscription period commences in IRLAB Therapeutics AB’s (“IRLAB” or the “Company”) issue of ordinary shares of series A with preferential rights for existing shareholders up to approximately SEK 68 million (the “Rights Issue”), which was resolved by the Board of Directors on 5 May 2026 and was approved by the Extraordinary General Meeting on 5 June 2026. The subscription period in the Rights Issue will run until 25 June 2026. However, please note that certain banks and nominees may apply an earlier deadline for subscription. Shareholders are therefore advised to check with their bank or nominee regarding any earlier deadline that may apply.

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.

Summary of the Rights Issue

The Rights Issue comprises a maximum of 56,625,346 ordinary shares of series A and upon full subscription in the Rights Issue, IRLAB will receive approximately SEK 68 million, before deduction of issue-related costs for the Rights Issue.

The subscription price is SEK 1.20 per share.

Anyone who was registered in the share register as a shareholder in IRLAB on the record date of 9 June 2026 received one (1) subscription right for each (1) share held, regardless of share series.

Three (3) subscription rights entitle to subscription of two (2) newly issued ordinary shares of series A.

The Rights Issue is covered to approximately 84 percent by subscription undertakings from existing shareholders and new investors, corresponding to approximately SEK 56.8 million. In addition, the Company has received a subscription intention of approximately SEK 4.9 million, corresponding to approximately 7.2 percent of the Rights Issue, consisting of expressed, non-binding, intention to subscribe for shares in the Rights Issue.

In total, approximately 91 percent of the Rights Issue is thus covered by subscription undertakings and subscription intentions.

Shareholders who choose not to participate in the Rights Issue will have their ownership interest diluted by up to approximately 40 percent, but have the opportunity to financially compensate themselves for the dilution effect by selling their subscription rights.

Full terms and conditions for the Rights Issue and other information about the Company are set out in the information document published by the Company on 5 June 2026.

The information document and other information about the Rights Issue is available on IRLAB’s website, www.irlab.se, and Aqurat Fondkommission AB’s website, www.aqurat.se.

Indicative timetable for the Rights Issue

The timetable below for the Rights Issue is preliminary and may be subject to change.

Trading in subscription rights 11 – 22 June 2026
Subscription period 11 – 25 June 2026
Trading in paid subscribed shares (BTA) 11 June 2026 up to and including approximately week 28, 2026
Expected day for announcement of the outcome 29 June 2026

Advisers

MAQS Advokatbyrå AB is legal advisor and Zonda Partners AB acts as financial advisor to the Company in connection with the Rights Issue. Aqurat Fondkommission AB is issuing agent in connection with the Rights Issue.